No Data
Guangdong Hybribio Biotech (300639.SZ): Has not yet begun the first buyback.
On December 2, Gelonhui | guangdong hybribio biotech (300639.SZ) announced that as of November 30, 2024, the company's third centralized competitive bidding method to repurchase company shares in 2024 has not yet begun the first repurchase.
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted an invention patent.
grlonghui December 2nd | guangdong hybribio biotech (300639.SZ) announced that the company and its subsidiaries were granted one invention patent in November 2024, with the invention patent titled a method for isolating placenta trophoblast cells from cervical sloughing cells of pregnant women. The invention patent discloses a method for isolating placenta trophoblast cells from cervical sloughing cells of pregnant women, which is based on the specific antigens and combinations expressed on the surface or intracellularly of trophoblast cells, and utilizes a designed microfluidic sorting chip or flow cytometer to sort the cell suspension prepared from cervical sloughing cell samples of pregnant women, thereby obtaining purified placenta.
Hybribio Biotech to Apply for 70 Million Yuan for Share Buyback Plan
Guangdong Hybribio Biotech (300639.SZ): Plans to spend 0.05 billion yuan to -0.1 billion yuan to buy back shares.
Gelonghui, November 14 – Guangdong Hybribio Biotech (300639.SZ) announced that the company plans to use its own funds and bank special repurchase loan funds to repurchase a portion of its shares through a centralized bidding trading method (hereinafter referred to as "this repurchase plan"). The repurchased shares will be used to maintain the company's value and the rights of shareholders. The total amount of funds for repurchasing shares and the source of funds will be no less than 50 million RMB (inclusive) and no more than 100 million RMB (inclusive) from its own funds and bank special repurchase loan funds. The price for repurchased shares will not exceed 9.00 RMB/share (inclusive). The implementation period for the repurchased shares starts from
Guangdong Hybribio Biotech (300639.SZ): The company currently has no test reagents related to dengue virus.
On November 14, Gelonghui reported that guangdong hybribio biotech (300639.SZ) stated on the investor interaction platform that the company currently has no test reagents related to the dengue virus, but its medical laboratory has the capability to perform laboratory tests for the dengue virus.
Individual Investors Are Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥378m Last Week
No Data
